nodes	percent_of_prediction	percent_of_DWPC	metapath
Alendronate—PTPN4—bronchus—esophageal cancer	0.0686	0.117	CbGeAlD
Alendronate—PTPN4—digestive system—esophageal cancer	0.053	0.0903	CbGeAlD
Alendronate—PTPRE—lung—esophageal cancer	0.0465	0.0793	CbGeAlD
Alendronate—PTPN4—lung—esophageal cancer	0.0443	0.0754	CbGeAlD
Alendronate—PTPRS—lung—esophageal cancer	0.0379	0.0647	CbGeAlD
Alendronate—ATP6V1A—bronchus—esophageal cancer	0.0339	0.0578	CbGeAlD
Alendronate—PTPRE—lymph node—esophageal cancer	0.0318	0.0542	CbGeAlD
Alendronate—ATP6V1A—trachea—esophageal cancer	0.0305	0.0519	CbGeAlD
Alendronate—PTPN4—lymph node—esophageal cancer	0.0303	0.0516	CbGeAlD
Alendronate—ATP6V1A—digestive system—esophageal cancer	0.0262	0.0446	CbGeAlD
Alendronate—PTPRS—lymph node—esophageal cancer	0.026	0.0442	CbGeAlD
Alendronate—FDPS—bronchus—esophageal cancer	0.0255	0.0435	CbGeAlD
Alendronate—FDPS—smooth muscle tissue—esophageal cancer	0.025	0.0426	CbGeAlD
Alendronate—FDPS—trachea—esophageal cancer	0.0229	0.0391	CbGeAlD
Alendronate—ATP6V1A—lung—esophageal cancer	0.0219	0.0373	CbGeAlD
Alendronate—FDPS—digestive system—esophageal cancer	0.0197	0.0336	CbGeAlD
Alendronate—Zoledronate—CA2—esophageal cancer	0.0191	0.521	CrCbGaD
Alendronate—FDPS—lung—esophageal cancer	0.0165	0.0281	CbGeAlD
Alendronate—ATP6V1A—lymph node—esophageal cancer	0.015	0.0255	CbGeAlD
Alendronate—Gastrointestinal tract irritation—Capecitabine—esophageal cancer	0.0145	0.0385	CcSEcCtD
Alendronate—Leukaemia—Methotrexate—esophageal cancer	0.0143	0.038	CcSEcCtD
Alendronate—Oesophageal ulcer—Capecitabine—esophageal cancer	0.0142	0.0377	CcSEcCtD
Alendronate—FDPS—lymph node—esophageal cancer	0.0113	0.0192	CbGeAlD
Alendronate—Joint swelling—Capecitabine—esophageal cancer	0.0105	0.028	CcSEcCtD
Alendronate—Lymphopenia—Capecitabine—esophageal cancer	0.0101	0.0269	CcSEcCtD
Alendronate—Risedronate—PTGS2—esophageal cancer	0.0093	0.253	CrCbGaD
Alendronate—Impaired healing—Methotrexate—esophageal cancer	0.0089	0.0237	CcSEcCtD
Alendronate—Gastric ulcer—Capecitabine—esophageal cancer	0.0089	0.0237	CcSEcCtD
Alendronate—Infection—Carboplatin—esophageal cancer	0.00848	0.0225	CcSEcCtD
Alendronate—Clodronate—PTGS2—esophageal cancer	0.00829	0.226	CrCbGaD
Alendronate—Hypercalcaemia—Capecitabine—esophageal cancer	0.00745	0.0198	CcSEcCtD
Alendronate—Ulcer—Cisplatin—esophageal cancer	0.00742	0.0197	CcSEcCtD
Alendronate—Pain—Carboplatin—esophageal cancer	0.0073	0.0194	CcSEcCtD
Alendronate—Body temperature increased—Carboplatin—esophageal cancer	0.00675	0.0179	CcSEcCtD
Alendronate—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00573	0.0152	CcSEcCtD
Alendronate—Hypocalcaemia—Capecitabine—esophageal cancer	0.00565	0.015	CcSEcCtD
Alendronate—Ulcer—Capecitabine—esophageal cancer	0.00547	0.0145	CcSEcCtD
Alendronate—Melaena—Capecitabine—esophageal cancer	0.00505	0.0134	CcSEcCtD
Alendronate—Influenza like illness—Capecitabine—esophageal cancer	0.00502	0.0134	CcSEcCtD
Alendronate—Oesophagitis—Capecitabine—esophageal cancer	0.00473	0.0126	CcSEcCtD
Alendronate—Cramp muscle—Cisplatin—esophageal cancer	0.00459	0.0122	CcSEcCtD
Alendronate—Photosensitivity—Capecitabine—esophageal cancer	0.00428	0.0114	CcSEcCtD
Alendronate—Abdominal discomfort—Cisplatin—esophageal cancer	0.00422	0.0112	CcSEcCtD
Alendronate—Ulcer—Methotrexate—esophageal cancer	0.00407	0.0108	CcSEcCtD
Alendronate—Stomatitis—Cisplatin—esophageal cancer	0.00383	0.0102	CcSEcCtD
Alendronate—Melaena—Methotrexate—esophageal cancer	0.00376	0.01	CcSEcCtD
Alendronate—Dry skin—Capecitabine—esophageal cancer	0.00344	0.00915	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00338	0.00899	CcSEcCtD
Alendronate—Gastritis—Capecitabine—esophageal cancer	0.00332	0.00883	CcSEcCtD
Alendronate—Abdominal distension—Capecitabine—esophageal cancer	0.00327	0.00868	CcSEcCtD
Alendronate—Dysphagia—Capecitabine—esophageal cancer	0.00325	0.00863	CcSEcCtD
Alendronate—Asthma—Capecitabine—esophageal cancer	0.00325	0.00863	CcSEcCtD
Alendronate—Photosensitivity—Methotrexate—esophageal cancer	0.00318	0.00846	CcSEcCtD
Alendronate—Alopecia—Cisplatin—esophageal cancer	0.00311	0.00828	CcSEcCtD
Alendronate—Abdominal discomfort—Capecitabine—esophageal cancer	0.00311	0.00827	CcSEcCtD
Alendronate—Erythema—Cisplatin—esophageal cancer	0.00307	0.00815	CcSEcCtD
Alendronate—Flatulence—Cisplatin—esophageal cancer	0.00302	0.00804	CcSEcCtD
Alendronate—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00296	0.00787	CcSEcCtD
Alendronate—Muscle spasms—Cisplatin—esophageal cancer	0.00295	0.00784	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00287	0.00763	CcSEcCtD
Alendronate—Ill-defined disorder—Cisplatin—esophageal cancer	0.00285	0.00757	CcSEcCtD
Alendronate—Anaemia—Cisplatin—esophageal cancer	0.00284	0.00754	CcSEcCtD
Alendronate—Stomatitis—Capecitabine—esophageal cancer	0.00282	0.0075	CcSEcCtD
Alendronate—Malaise—Cisplatin—esophageal cancer	0.00277	0.00735	CcSEcCtD
Alendronate—Myalgia—Cisplatin—esophageal cancer	0.00261	0.00694	CcSEcCtD
Alendronate—Haemoglobin—Capecitabine—esophageal cancer	0.00261	0.00694	CcSEcCtD
Alendronate—Haemorrhage—Capecitabine—esophageal cancer	0.0026	0.0069	CcSEcCtD
Alendronate—Discomfort—Cisplatin—esophageal cancer	0.00258	0.00686	CcSEcCtD
Alendronate—Oedema peripheral—Capecitabine—esophageal cancer	0.00256	0.0068	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00252	0.00669	CcSEcCtD
Alendronate—Infection—Cisplatin—esophageal cancer	0.00249	0.00661	CcSEcCtD
Alendronate—Erythema multiforme—Capecitabine—esophageal cancer	0.00246	0.00653	CcSEcCtD
Alendronate—Asthma—Methotrexate—esophageal cancer	0.00242	0.00642	CcSEcCtD
Alendronate—Abdominal discomfort—Methotrexate—esophageal cancer	0.00232	0.00616	CcSEcCtD
Alendronate—Alopecia—Capecitabine—esophageal cancer	0.0023	0.0061	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00228	0.00606	CcSEcCtD
Alendronate—Erythema—Capecitabine—esophageal cancer	0.00226	0.00601	CcSEcCtD
Alendronate—Flatulence—Capecitabine—esophageal cancer	0.00223	0.00592	CcSEcCtD
Alendronate—Dysgeusia—Capecitabine—esophageal cancer	0.00221	0.00589	CcSEcCtD
Alendronate—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00221	0.00586	CcSEcCtD
Alendronate—Muscle spasms—Capecitabine—esophageal cancer	0.00217	0.00578	CcSEcCtD
Alendronate—Pain—Cisplatin—esophageal cancer	0.00214	0.00569	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00214	0.00568	CcSEcCtD
Alendronate—Stomatitis—Methotrexate—esophageal cancer	0.0021	0.00558	CcSEcCtD
Alendronate—Ill-defined disorder—Capecitabine—esophageal cancer	0.0021	0.00558	CcSEcCtD
Alendronate—Anaemia—Capecitabine—esophageal cancer	0.00209	0.00556	CcSEcCtD
Alendronate—Feeling abnormal—Cisplatin—esophageal cancer	0.00206	0.00548	CcSEcCtD
Alendronate—Malaise—Capecitabine—esophageal cancer	0.00204	0.00542	CcSEcCtD
Alendronate—Vertigo—Capecitabine—esophageal cancer	0.00203	0.0054	CcSEcCtD
Alendronate—Body temperature increased—Cisplatin—esophageal cancer	0.00198	0.00526	CcSEcCtD
Alendronate—Haemoglobin—Methotrexate—esophageal cancer	0.00194	0.00517	CcSEcCtD
Alendronate—Haemorrhage—Methotrexate—esophageal cancer	0.00193	0.00514	CcSEcCtD
Alendronate—Myalgia—Capecitabine—esophageal cancer	0.00193	0.00512	CcSEcCtD
Alendronate—Chest pain—Capecitabine—esophageal cancer	0.00193	0.00512	CcSEcCtD
Alendronate—Discomfort—Capecitabine—esophageal cancer	0.0019	0.00506	CcSEcCtD
Alendronate—Hypersensitivity—Cisplatin—esophageal cancer	0.00184	0.0049	CcSEcCtD
Alendronate—Infection—Capecitabine—esophageal cancer	0.00183	0.00487	CcSEcCtD
Alendronate—Erythema multiforme—Methotrexate—esophageal cancer	0.00183	0.00486	CcSEcCtD
Alendronate—Asthenia—Cisplatin—esophageal cancer	0.0018	0.00477	CcSEcCtD
Alendronate—Diarrhoea—Cisplatin—esophageal cancer	0.00171	0.00455	CcSEcCtD
Alendronate—Alopecia—Methotrexate—esophageal cancer	0.00171	0.00454	CcSEcCtD
Alendronate—Erythema—Methotrexate—esophageal cancer	0.00168	0.00447	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00168	0.00447	CcSEcCtD
Alendronate—Dysgeusia—Methotrexate—esophageal cancer	0.00165	0.00438	CcSEcCtD
Alendronate—Dyspepsia—Capecitabine—esophageal cancer	0.00162	0.00432	CcSEcCtD
Alendronate—Vomiting—Cisplatin—esophageal cancer	0.00159	0.00423	CcSEcCtD
Alendronate—Rash—Cisplatin—esophageal cancer	0.00158	0.0042	CcSEcCtD
Alendronate—Pain—Capecitabine—esophageal cancer	0.00158	0.0042	CcSEcCtD
Alendronate—Constipation—Capecitabine—esophageal cancer	0.00158	0.0042	CcSEcCtD
Alendronate—Dermatitis—Cisplatin—esophageal cancer	0.00158	0.00419	CcSEcCtD
Alendronate—Ill-defined disorder—Methotrexate—esophageal cancer	0.00156	0.00415	CcSEcCtD
Alendronate—Anaemia—Methotrexate—esophageal cancer	0.00156	0.00414	CcSEcCtD
Alendronate—Feeling abnormal—Capecitabine—esophageal cancer	0.00152	0.00404	CcSEcCtD
Alendronate—Malaise—Methotrexate—esophageal cancer	0.00152	0.00404	CcSEcCtD
Alendronate—Vertigo—Methotrexate—esophageal cancer	0.00151	0.00402	CcSEcCtD
Alendronate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00151	0.00401	CcSEcCtD
Alendronate—Nausea—Cisplatin—esophageal cancer	0.00149	0.00395	CcSEcCtD
Alendronate—Urticaria—Capecitabine—esophageal cancer	0.00147	0.0039	CcSEcCtD
Alendronate—Abdominal pain—Capecitabine—esophageal cancer	0.00146	0.00388	CcSEcCtD
Alendronate—Body temperature increased—Capecitabine—esophageal cancer	0.00146	0.00388	CcSEcCtD
Alendronate—Chest pain—Methotrexate—esophageal cancer	0.00143	0.00381	CcSEcCtD
Alendronate—Myalgia—Methotrexate—esophageal cancer	0.00143	0.00381	CcSEcCtD
Alendronate—Discomfort—Methotrexate—esophageal cancer	0.00142	0.00376	CcSEcCtD
Alendronate—Infection—Methotrexate—esophageal cancer	0.00137	0.00363	CcSEcCtD
Alendronate—Hypersensitivity—Capecitabine—esophageal cancer	0.00136	0.00361	CcSEcCtD
Alendronate—Asthenia—Capecitabine—esophageal cancer	0.00132	0.00352	CcSEcCtD
Alendronate—Pruritus—Capecitabine—esophageal cancer	0.00131	0.00347	CcSEcCtD
Alendronate—Diarrhoea—Capecitabine—esophageal cancer	0.00126	0.00336	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00125	0.00333	CcSEcCtD
Alendronate—Dizziness—Capecitabine—esophageal cancer	0.00122	0.00324	CcSEcCtD
Alendronate—Dyspepsia—Methotrexate—esophageal cancer	0.00121	0.00321	CcSEcCtD
Alendronate—Pain—Methotrexate—esophageal cancer	0.00117	0.00312	CcSEcCtD
Alendronate—Vomiting—Capecitabine—esophageal cancer	0.00117	0.00312	CcSEcCtD
Alendronate—Rash—Capecitabine—esophageal cancer	0.00116	0.00309	CcSEcCtD
Alendronate—Dermatitis—Capecitabine—esophageal cancer	0.00116	0.00309	CcSEcCtD
Alendronate—Headache—Capecitabine—esophageal cancer	0.00116	0.00307	CcSEcCtD
Alendronate—Feeling abnormal—Methotrexate—esophageal cancer	0.00113	0.00301	CcSEcCtD
Alendronate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00112	0.00299	CcSEcCtD
Alendronate—Nausea—Capecitabine—esophageal cancer	0.0011	0.00291	CcSEcCtD
Alendronate—Urticaria—Methotrexate—esophageal cancer	0.00109	0.0029	CcSEcCtD
Alendronate—Body temperature increased—Methotrexate—esophageal cancer	0.00109	0.00289	CcSEcCtD
Alendronate—Abdominal pain—Methotrexate—esophageal cancer	0.00109	0.00289	CcSEcCtD
Alendronate—Hypersensitivity—Methotrexate—esophageal cancer	0.00101	0.00269	CcSEcCtD
Alendronate—Asthenia—Methotrexate—esophageal cancer	0.000986	0.00262	CcSEcCtD
Alendronate—Pruritus—Methotrexate—esophageal cancer	0.000972	0.00258	CcSEcCtD
Alendronate—Diarrhoea—Methotrexate—esophageal cancer	0.00094	0.0025	CcSEcCtD
Alendronate—Dizziness—Methotrexate—esophageal cancer	0.000909	0.00241	CcSEcCtD
Alendronate—Vomiting—Methotrexate—esophageal cancer	0.000874	0.00232	CcSEcCtD
Alendronate—Rash—Methotrexate—esophageal cancer	0.000866	0.0023	CcSEcCtD
Alendronate—Dermatitis—Methotrexate—esophageal cancer	0.000866	0.0023	CcSEcCtD
Alendronate—Headache—Methotrexate—esophageal cancer	0.000861	0.00229	CcSEcCtD
Alendronate—Nausea—Methotrexate—esophageal cancer	0.000816	0.00217	CcSEcCtD
Alendronate—PTPRE—IL6-mediated signaling events—MYC—esophageal cancer	1.09e-05	0.0652	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—PIK3CA—esophageal cancer	9.26e-06	0.0553	CbGpPWpGaD
Alendronate—ATP6V1A—Iron uptake and transport—HMOX1—esophageal cancer	8.63e-06	0.0516	CbGpPWpGaD
Alendronate—ATP6V1A—Latent infection of Homo sapiens with Mycobacterium tuberculosis—NOS2—esophageal cancer	7.44e-06	0.0444	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—MMP14—esophageal cancer	6.96e-06	0.0416	CbGpPWpGaD
Alendronate—ATP6V1A—Latent infection of Homo sapiens with Mycobacterium tuberculosis—NOS3—esophageal cancer	5.98e-06	0.0357	CbGpPWpGaD
Alendronate—FDPS—Activation of gene expression by SREBF (SREBP)—CREBBP—esophageal cancer	4.69e-06	0.028	CbGpPWpGaD
Alendronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CREBBP—esophageal cancer	3.74e-06	0.0224	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—KDR—esophageal cancer	3.11e-06	0.0186	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	3.04e-06	0.0182	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	2.86e-06	0.0171	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	2.71e-06	0.0162	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—AQP3—esophageal cancer	2.59e-06	0.0155	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	2.56e-06	0.0153	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ATP4A—esophageal cancer	2.48e-06	0.0148	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	2.48e-06	0.0148	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—SLC52A3—esophageal cancer	2e-06	0.012	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—KMT2D—esophageal cancer	1.91e-06	0.0114	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ABCC2—esophageal cancer	1.88e-06	0.0112	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—GDI2—esophageal cancer	1.85e-06	0.011	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	1.73e-06	0.0103	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—GNG7—esophageal cancer	1.71e-06	0.0102	CbGpPWpGaD
Alendronate—FDPS—SREBP signalling—PIK3CA—esophageal cancer	1.53e-06	0.00912	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	1.51e-06	0.00901	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—FKBP1A—esophageal cancer	1.48e-06	0.00884	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—WIF1—esophageal cancer	1.45e-06	0.00864	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—DOCK2—esophageal cancer	1.45e-06	0.00864	CbGpPWpGaD
Alendronate—FDPS—Metabolism—BLVRB—esophageal cancer	1.34e-06	0.00801	CbGpPWpGaD
Alendronate—FDPS—Metabolism—SLC52A3—esophageal cancer	1.34e-06	0.00801	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KMT2D—esophageal cancer	1.34e-06	0.00799	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CSNK1A1—esophageal cancer	1.34e-06	0.00798	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—PIK3CA—esophageal cancer	1.26e-06	0.00753	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	1.2e-06	0.00716	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ADCYAP1—esophageal cancer	1.19e-06	0.00712	CbGpPWpGaD
Alendronate—FDPS—Metabolism—SLC10A2—esophageal cancer	1.14e-06	0.00681	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CA1—esophageal cancer	1.14e-06	0.00681	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ELMO1—esophageal cancer	1.12e-06	0.0067	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TPI1—esophageal cancer	1.1e-06	0.00655	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—GSTO1—esophageal cancer	1.1e-06	0.00655	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—WWOX—esophageal cancer	1.09e-06	0.00651	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ALDOB—esophageal cancer	1.05e-06	0.00628	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CA2—esophageal cancer	1.04e-06	0.00623	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.04e-06	0.00621	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—FKBP1A—esophageal cancer	1.04e-06	0.00619	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.02e-06	0.00608	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—WIF1—esophageal cancer	1.01e-06	0.00605	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HIST1H2BM—esophageal cancer	1.01e-06	0.00605	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—GAPDH—esophageal cancer	1.01e-06	0.00605	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ABCB1—esophageal cancer	9.98e-07	0.00596	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PLCE1—esophageal cancer	9.69e-07	0.00579	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ADH7—esophageal cancer	9.69e-07	0.00579	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	9.58e-07	0.00572	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CSNK1A1—esophageal cancer	9.35e-07	0.00559	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—XIAP—esophageal cancer	8.94e-07	0.00534	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PFN1—esophageal cancer	8.75e-07	0.00523	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ADH1B—esophageal cancer	8.5e-07	0.00508	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—B2M—esophageal cancer	8.31e-07	0.00497	CbGpPWpGaD
Alendronate—FDPS—Metabolism—TYMP—esophageal cancer	8.12e-07	0.00485	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ENO1—esophageal cancer	7.97e-07	0.00476	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYP26A1—esophageal cancer	7.9e-07	0.00472	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ELMO1—esophageal cancer	7.86e-07	0.00469	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PSME2—esophageal cancer	7.85e-07	0.00469	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PSME1—esophageal cancer	7.85e-07	0.00469	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ALOX15—esophageal cancer	7.7e-07	0.0046	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—AKAP13—esophageal cancer	7.68e-07	0.00459	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CALR—esophageal cancer	7.54e-07	0.0045	CbGpPWpGaD
Alendronate—FDPS—Metabolism—TPI1—esophageal cancer	7.34e-07	0.00439	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTO1—esophageal cancer	7.34e-07	0.00439	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—FBXW7—esophageal cancer	7.29e-07	0.00435	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HIST1H2BM—esophageal cancer	7.09e-07	0.00423	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ALDOB—esophageal cancer	7.04e-07	0.00421	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PDE4D—esophageal cancer	7.02e-07	0.0042	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GAPDH—esophageal cancer	6.78e-07	0.00405	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CRABP1—esophageal cancer	6.72e-07	0.00401	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—GNG7—esophageal cancer	6.68e-07	0.00399	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—CREBBP—esophageal cancer	6.67e-07	0.00398	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GNG7—esophageal cancer	6.39e-07	0.00382	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—XIAP—esophageal cancer	6.26e-07	0.00374	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ALDH2—esophageal cancer	5.99e-07	0.00358	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CTNNA1—esophageal cancer	5.92e-07	0.00354	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TGFBR2—esophageal cancer	5.89e-07	0.00352	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CXCL2—esophageal cancer	5.89e-07	0.00352	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTT1—esophageal cancer	5.69e-07	0.0034	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYP2A6—esophageal cancer	5.63e-07	0.00336	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.61e-07	0.00335	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—SMAD4—esophageal cancer	5.58e-07	0.00333	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PSME1—esophageal cancer	5.5e-07	0.00328	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PSME2—esophageal cancer	5.5e-07	0.00328	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ANXA1—esophageal cancer	5.47e-07	0.00327	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTGS1—esophageal cancer	5.34e-07	0.00319	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ENO1—esophageal cancer	5.34e-07	0.00319	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—SST—esophageal cancer	5.32e-07	0.00318	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PSME2—esophageal cancer	5.26e-07	0.00314	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PSME1—esophageal cancer	5.26e-07	0.00314	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—GHRL—esophageal cancer	5.19e-07	0.0031	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NOTCH3—esophageal cancer	5.19e-07	0.0031	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—FBXW7—esophageal cancer	5.1e-07	0.00305	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NOTCH2—esophageal cancer	4.65e-07	0.00278	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.59e-07	0.00274	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HIF1A—esophageal cancer	4.57e-07	0.00273	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYP1B1—esophageal cancer	4.54e-07	0.00271	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYP19A1—esophageal cancer	4.27e-07	0.00255	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—NOS2—esophageal cancer	4.15e-07	0.00248	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TGFBR2—esophageal cancer	4.13e-07	0.00247	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—NOTCH1—esophageal cancer	4.11e-07	0.00246	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—SMAD4—esophageal cancer	3.91e-07	0.00233	CbGpPWpGaD
Alendronate—FDPS—Metabolism—HMOX1—esophageal cancer	3.89e-07	0.00232	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.82e-07	0.00228	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ABCB1—esophageal cancer	3.74e-07	0.00223	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CREBBP—esophageal cancer	3.73e-07	0.00223	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—NOS3—esophageal cancer	3.34e-07	0.00199	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HIF1A—esophageal cancer	3.2e-07	0.00191	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ERBB2—esophageal cancer	3.12e-07	0.00187	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KDR—esophageal cancer	3.06e-07	0.00183	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PTGS2—esophageal cancer	3.05e-07	0.00182	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NOTCH1—esophageal cancer	2.88e-07	0.00172	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.82e-07	0.00169	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CDKN1A—esophageal cancer	2.67e-07	0.00159	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CREBBP—esophageal cancer	2.61e-07	0.00156	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—EP300—esophageal cancer	2.54e-07	0.00152	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CREBBP—esophageal cancer	2.5e-07	0.00149	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NOS3—esophageal cancer	2.34e-07	0.0014	CbGpPWpGaD
Alendronate—FDPS—Metabolism—NOS3—esophageal cancer	2.24e-07	0.00134	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MYC—esophageal cancer	2.21e-07	0.00132	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ERBB2—esophageal cancer	2.19e-07	0.00131	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—EGFR—esophageal cancer	2.16e-07	0.00129	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTGS2—esophageal cancer	2.04e-07	0.00122	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CCND1—esophageal cancer	1.93e-07	0.00115	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PIK3CA—esophageal cancer	1.88e-07	0.00112	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CDKN1A—esophageal cancer	1.87e-07	0.00112	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—EP300—esophageal cancer	1.78e-07	0.00106	CbGpPWpGaD
Alendronate—FDPS—Metabolism—EP300—esophageal cancer	1.7e-07	0.00102	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MYC—esophageal cancer	1.55e-07	0.000926	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—EGFR—esophageal cancer	1.52e-07	0.000906	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CA—esophageal cancer	1.32e-07	0.000786	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TP53—esophageal cancer	1.27e-07	0.00076	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CA—esophageal cancer	1.26e-07	0.000751	CbGpPWpGaD
